148 related articles for article (PubMed ID: 10857990)
1. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.
Monks A; Harris ED; Vaigro-Wolff A; Hose CD; Connelly JW; Sausville EA
Invest New Drugs; 2000 May; 18(2):95-107. PubMed ID: 10857990
[TBL] [Abstract][Full Text] [Related]
2. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation.
Sugiyama K; Shimizu M; Akiyama T; Tamaoki T; Yamaguchi K; Takahashi R; Eastman A; Akinaga S
Int J Cancer; 2000 Mar; 85(5):703-9. PubMed ID: 10699952
[TBL] [Abstract][Full Text] [Related]
3. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM
J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426
[TBL] [Abstract][Full Text] [Related]
4. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.
Husain A; Yan XJ; Rosales N; Aghajanian C; Schwartz GK; Spriggs DR
Clin Cancer Res; 1997 Nov; 3(11):2089-97. PubMed ID: 9815601
[TBL] [Abstract][Full Text] [Related]
5. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.
Eastman A; Kohn EA; Brown MK; Rathman J; Livingstone M; Blank DH; Gribble GW
Mol Cancer Ther; 2002 Oct; 1(12):1067-78. PubMed ID: 12481430
[TBL] [Abstract][Full Text] [Related]
6. UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells.
Jones CB; Clements MK; Redkar A; Daoud SS
Int J Oncol; 2000 Nov; 17(5):1043-51. PubMed ID: 11029511
[TBL] [Abstract][Full Text] [Related]
7. Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Bozko P; Larsen AK; Raymond E; Skladanowski A
Acta Biochim Pol; 2002; 49(1):109-19. PubMed ID: 12136930
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
Mack PC; Gandara DR; Lau AH; Lara PN; Edelman MJ; Gumerlock PH
Cancer Chemother Pharmacol; 2003 Apr; 51(4):337-48. PubMed ID: 12721762
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines.
Lee SI; Brown MK; Eastman A
Biochem Pharmacol; 1999 Dec; 58(11):1713-21. PubMed ID: 10571245
[TBL] [Abstract][Full Text] [Related]
10. Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.
Redkar A; Mixter P; Daoud SS
J Exp Ther Oncol; 2004 Oct; 4(3):213-22. PubMed ID: 15724841
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.
Akinaga S; Nomura K; Gomi K; Okabe M
Cancer Chemother Pharmacol; 1993; 32(3):183-9. PubMed ID: 8500222
[TBL] [Abstract][Full Text] [Related]
13. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
Byrd JC; Shinn C; Willis CR; Flinn IW; Lehman T; Sausville E; Lucas D; Grever MR
Exp Hematol; 2001 Jun; 29(6):703-8. PubMed ID: 11378265
[TBL] [Abstract][Full Text] [Related]
14. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK
Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.
Shao RG; Cao CX; Shimizu T; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1997 Sep; 57(18):4029-35. PubMed ID: 9307289
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.
Bunch RT; Eastman A
Clin Cancer Res; 1996 May; 2(5):791-7. PubMed ID: 9816232
[TBL] [Abstract][Full Text] [Related]
18. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
[TBL] [Abstract][Full Text] [Related]
20. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53.
Shao RG; Shimizu T; Pommier Y
Exp Cell Res; 1997 Aug; 234(2):388-97. PubMed ID: 9260909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
